Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23067570 | 0.87 | CRBN (0.54) | CRBNSIGMAR1DRD2HTR2AHTR2C | |
| SCHEMBL22018722 | 0.85 | CRBN (0.49) | CRBNDDB1CXCR3 | |
| SCHEMBL19586513 | 0.84 | CRBN (0.55) | CRBNALDH1A1CYP2D6CYP2C9DDB1 | |
| SCHEMBL1042820 | 0.81 | SIGMAR1 (0.53) | CRBNSIGMAR1DRD2HTR2AHTR2C | |
| SCHEMBL3268276 | 0.80 | LTA4H (0.54) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL22932162 | 0.77 | CRBN (0.60) | CRBNSIGMAR1DRD2ALDH1A1 | |
| SCHEMBL21496474 | 0.76 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL22932066 | 0.76 | CRBN (0.50) | CRBN | |
| SCHEMBL22932062 | 0.75 | CRBN (0.67) | CRBN | |
| SCHEMBL13090069 | 0.75 | NR3C1 (0.52) | SIGMAR1DRD2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751456-A | Spiro compounds | C4医药公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-03-27 | — | — | US | disclosed |
| CN-112312904-B | Spiro compounds | C4医药公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4384521-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| CN-117794936-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-03-29 | — | — | CN | disclosed |
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018237-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| EP-3781156-A1 | SPIROCYCLIC COMPOUNDS | C4 Therapeutics, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| WO-2019204354-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885SIGMAR1 4265/4885DRD2 4476/4885 |
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRBN 1/4885SIGMAR1 4050/4885DRD2 4192/4885 |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRBN 1/4885SIGMAR1 4050/4885DRD2 4192/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | CRBN 1/4885SIGMAR1 4050/4885DRD2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.